Sozen T, Ozisik L, Calik Basaran N. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46–56.

Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16:1–82.

Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey E V, et al. Osteoporosis: burden, health care provision and opportunities in the EU. Arch Osteoporos. 2011;6:59–155.

Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML, et al. Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int. 2017.

Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8(137):1–218.

Van Geel TACM, Van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68:99–102.

Marcellusi A, Rotundo MA, Nardone C, Sciattella P, Gazzillo S, Rossini M, et al. Osteoporosis: economic burden of disease in Italy. Clin Drug Investig. 2020;40(5):449–58.

Klop C, van Staa TP, Cooper C, Harvey NC, de Vries F. The epidemiology of mortality after fracture in England: variation by age, sex, time, geographic location, and ethnicity. Osteoporos Int. 2017;28(1):161–8.

Bliuc D, Nguyen ND, Milch VE, Nguyen T V., Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513–21.

Tran T, Bliuc D, van Geel T, Adachi JD, Berger C, van den Bergh J, et al. Population-wide impact of non-hip non-vertebral fractures on mortality. J Bone Miner Res. 2017;32(9):1802-–10.

McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E, et al. The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int. 2021;32(2):251–9.

Fardellone P, Barnieh L, Quignot N, Gusto G, Kahangire DA, Worth G, et al. The clinical and economic burden after an osteoporosis fracture in France: a nationwide population-based study. Arch Osteoporos. 2021;16(124):1–9.

Martínez-Laguna D, Carbonell C, Bastida JC, González M, Micó-Pérez RM, Vargas F, et al. Prevalence and treatment of fragility fractures in Spanish primary care: PREFRAOS study. Arch Osteoporos. 2022;17(93):1–9.

Böcker W, Doobaree IU, Khachatryan A, Dornstauder E, Bartsch R, Worth G, et al. Fractures in untreated patients with osteoporosis in Germany: an InGef healthcare insurance database analysis. Osteoporos Int. 2022;33(1):77–86.

Fardellone P, Barnieh L, Quignot N, Gusto G, Khachatryan A, Kahangire DA, et al. Exploring the treatment gap among patients with osteoporosis-related fractures in France. Arch Osteoporos. 2022;17(29):1–9.

Cortet B, Schott AM, Désaméricq G, Chauny JV, Samama P, Emery C, et al. Trends in postmenopausal osteoporosis treatment in France during the period 2007–2016: a nationwide claims database analysis. Bone. 2022;154:1–9.

Gerasimaviciute V, Mathur R, Mansfield KE, McDermott MP, Neasham DE, O’Kelly JL. Osteoporosis-related characteristics in care home residents in England: a retrospective cohort study. BJGP Open. 2023;7(2):1–12.

Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4):1–18.

Alahmari MM, AlHilali AI, Thabet TA, Alshahrani MA, Mobasher WA, Al Mubarak DA, et al. Impact of medication adherence on bone mineral density and fracture risk in patients with osteoporosis: a systematic review. Cureus. 2023;15(7):1–12.

Tariffari nazionali delle prestazioni del Ssn [Internet]. [cited 2024 Jun 19]. Available from: https://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3662&area=programmazioneSanitariaLea&menu=vuoto.

Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12.

Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280–8.

Agarwal AR, Cohen JS, Jorgensen A, Thakkar SC, Srikumaran U, Golladay GJ. Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019. Osteoporos Int. 2023;34(2):379–85.

Gonnelli S, Caffarelli C, Iolascon G, Bertoldo F, Letizia Mauro G, Patti A, et al. Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey. Aging Clin Exp Res. 2017;29(5):1031–7.

Iolascon G, Gimigliano F, Moretti A, Riccio I, Gennaro M Di, Illario M, et al. Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database. Clin Cases Miner Bone Metab. 2016;13(2):127–30.

Iolascon G, Gimigliano F, Orlando V, Capaldo A, Di Somma C, Menditto E. Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin Exp Res. 2013;25(1S):137–41.

Casula M, Catapano AL, Piccinelli R, Menditto E, Manzoli L, De Fendi L, et al. Assessment and potential determinants of compliance and persistence to antiosteoporosis therapy in Italy. Am J Manag Care. 2014;20(5):138–45.

des Bordes J, Prasad S, Pratt G, Suarez-Almazor ME, Lopez-Olivo MA. Knowledge, beliefs, and concerns about bone health from a systematic review and metasynthesis of qualitative studies. PLoS One. 2020;15(1):1–17.

De Martinis M, Sirufo MM, Polsinelli M, Placidi G, Di Silvestre D, Ginaldi L. Gender differences in osteoporosis: a single- center observational study. World J Mens Health. 2020;39(4):750–9.

Lespessailles E, Toumi H. Proton pump inhibitors and bone health: an update narrative review. Int J Mol Sci. 2022;23(18):1–10.

Paget SA. Overview of glucocorticoid-induced osteoporosis. Journal of Clinical Rheumatology. 1999.

Wongdee K. Osteoporosis in diabetes mellitus: possible cellular and molecular mechanisms. World J Diabetes. 2011;2(3):41–8.

Cornelissen D, de Kunder S, Si L, Reginster JY, Evers S, Boonen A, et al. Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int. 2020;31(9):1645–69.

Degli Esposti L, Adami S, Iolascon G, Nardi A, Pietrogrande L, Resmini G, et al. Cost of osteoporosis-related fracture in Italy. Results of the BLOCK study. Farmeconomia Health economics and therapeutic pathways. 2011;12(3):99–105.

Thomas T, Tubach F, Bizouard G, Crochard A, Maurel F, Perrin L, et al. The economic burden of severe osteoporotic fractures in the French healthcare database: the FRACTOS study. J Bone Miner Res. 2022;37(10):1811–22.

Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR. Economic burden of osteoporosis-related fractures in the US Medicare population. Ann Pharmacother. 2021;55(7):821–9.

Degli Esposti L, Saragoni S, Perrone V, Sella S, Andretta M, Rossini M, et al. Economic burden of osteoporotic patients with fracture: effect of treatment with or without calcium/vitamin D supplements. Nutr Diet Suppl. 2020;12:21–30.

Yeh EJ, Gitlin M, Sorio F, McCloskey E. Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among postmenopausal women across eight European countries. Arch Osteoporos. 2023;18(68):1–9.

Hagino H, Jackson M, Gitlin M, Wessler Z. Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in Japan: a simulation projection model from 2020 to 2040. Arch Osteoporos. 2021;16(1):156.

Cui L, Jackson M, Wessler Z, Gitlin M, Xia W. Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in China: a simulation projection model from 2020 to 2040. Arch Osteoporos. 2021;16(1):118.

Jackson M, Yang KH, Gitlin M, Wessler Z. Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in South Korea: a simulation projection model from 2020 to 2040. Arch Osteoporos. 2021;16(1):115.

Roux C, Thomas T, Paccou J, Bizouard G, Crochard A, Toth E, et al. Refracture and mortality following hospitalization for severe osteoporotic fractures: the Fractos Study. JBMR Plus. 2021;5(7):1–11.

Istituto Nazionale di Statistica (ISTAT). “demo.istat: Indicatori Demografici.” [Internet]. [cited 2024 Mar 18]. Available from: https://demo.istat.it/.

ISTAT. Bilancio demografico nazionale 2018. 2018.

Llopis-Cardona F, Armero C, Hurtado I, García-Sempere A, Peiró S, Rodríguez-Bernal CL, et al. Incidence of subsequent hip fracture and mortality in elderly patients: a multistate population-based cohort study in eastern Spain. J Bone Miner Res. 2022;37(6):1200–8.

Alves SM, Economou T, Oliveira C, Ribeiro AI, Neves N, Goméz-Barrena E, et al. Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective study. Bone. 2013;53(2):430–6.

PubMed  Google Scholar 

Lin JCF, Liang WM. Mortality and complications after hip fracture among elderly patients undergoing hemodialysis. BMC Nephrol. 2015;16(100):1–9.

Sicras-Mainar A, Sorio-Vilela F, Sacrest-Soy M, Gatell S, Sicras-Navarro A, Villoro-Valdés R, et al. Real-world osteoporosis treatment gap and costs in Spain: data from women with a first fragility fracture or diagnosis of postmenopausal osteoporosis. Rheumatol Ther. 2025;12(2):315–35.

PubMed  PubMed Central  Google Scholar